33 articles
Swiss researchers linked cancer drug approvals to real patient outcomes for the first time, revealing which treatments truly deliver survival benefits.
A minimally invasive knee osteoarthritis treatment called genicular artery embolization cut pain by 57% in patients who failed conventional therapies.
An NIH clinical trial found lifestyle changes beat medication for prediabetes, cutting risk of diabetes, heart disease, and kidney problems simultaneously.
Dupilumab shows promise for eosinophilic gastritis, while the FDA approves the first steroid-free topical psoriasis cream for children as young as 2.
NIH-funded medical research now costs scientists up to $12,850 per paper to publish openly, forcing researchers to choose between prestige journals and.
Adaptive deep brain stimulation cuts freezing of gait in Parkinson's patients, but FDA approval hinges on validating the algorithm, not the hardware.
Adding durvalumab to BCG improved bladder cancer survival rates, but caused serious side effects in 21% of patients versus just 4% with BCG alone.
A decades-old heart drug, spironolactone, showed promise for improving working memory in schizophrenia patients, addressing a cognitive gap no current.
MetALD, a liver disease combining alcohol use and metabolic dysfunction, affects millions and progresses faster than either condition alone.
Ultrasound-guided carpal tunnel surgery lets most patients return to work in four days, with zero complications reported across the largest U.S. study.
Federal agencies are replacing animal testing with lab-grown organs and AI models that better predict human drug responses and reduce failures.
A new OMB proposal could give political appointees control over medical research funding, replacing scientist-led peer review with political decisions.
FDA approves first major U.S. trial of ozone injection for herniated discs, testing whether this minimally invasive treatment can help 300 patients avoid.
Repatha cholesterol drug cuts heart attack risk by 29% in high-risk diabetes patients when added to statins, new clinical trial data reveals.
Multi-arm platform trials could end neurodegenerative disease research's 99.6% failure rate by testing multiple treatments simultaneously.
Semaglutide users face double the risk of rare vision-threatening condition NAION, though absolute risk remains low at 1 in 7,000 patients annually.
Semaglutide reduced heavy drinking days by 41% and total alcohol consumption by 70% in the first major trial for alcohol use disorder.
Night owls face higher migraine disability than early risers, new research shows, linking sleep timing to headache severity and functioning.
Standard PTSD therapies fail 39-72% of patients, but psychedelic-assisted therapy and nerve blocks offer new hope for trauma survivors.
A biotech company is launching the first FDA-compliant sildenafil cream designed specifically for women with arousal difficulties, addressing a...
A rigorous analysis of 7 randomized trials found technology-based interventions showed minimal impact on loneliness.
A new drug called endoxifen significantly reduced breast density, a key cancer risk factor, in healthy women with a tolerability profile similar to placebo,...
A systematic review of 14 studies reveals that educational programs significantly boost medication error reporting among nurses and healthcare staff,...
The NIH's All of Us Research Program released wearable data from over 59,000 participants, including 39 million step observations and 31 million sleep records.
A non-invasive brain stimulation device called HALO Clarity is entering a 160-person clinical trial to treat moderate-to-severe insomnia without medication.
FDA grants breakthrough designation to sofetabart mipitecan for hard-to-treat ovarian cancer.
A new precision oncology system is bringing advanced cancer clinical trials to community doctors' offices, not just academic hospitals.
The FDA is ending its decades-old requirement for two clinical trials to approve new drugs, now requiring just one rigorous study plus supporting evidence.
A new study shows that aflibercept 8 mg helps heavily treated wet macular degeneration patients extend treatment intervals from 4 to 6 weeks, with 35%...
A first-in-class drug called SPG601 showed unprecedented improvements in brain function and cognition in Fragile X Syndrome patients, with results published in...
A peer-reviewed pilot study found that a non-invasive brain stimulation technique reduced self-injury behaviors and depression in six female adolescents, with...
Over 27% of Americans take melatonin, but research shows it reduces sleep onset by just 7-11 minutes for general insomnia.
A critical analysis reveals how a widely-shared recreational drug ranking uses flawed methodology and selective framing to present subjective opinions as...
